Pharmanovia

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022🗂️ Report periods on file: 2022

In its 2022 reporting, Pharmanovia disclosed greenhouse gas emissions of 12.5K tCO2e/year. By scope: Scope 1: 60 tCO2e/year; Scope 2: 3 tCO2e/year; Scope 3: 12.4K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
12.5K tCO2e/year
2022

📊 Emissions by Scope (2022)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).60 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.3 tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).12.4K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Increase the number of sea shipments to 40% by the end of 2023.

📅 Medium-term

  • Reduce absolute Scope 1 and 2 emissions by 42% by 2030 from a 2021 base year.
  • Measure and manage Scope 3 emissions, ensuring no growth in absolute Scope 3 emissions.
  • Offset 100% of remaining emissions by 2030.

🌱 ESG Focus Areas

Patient health and safetyProduct qualityEthical business practicesProduct InnovationHuman capital and cultureGovernanceResponsible supply chainEnvironmental Impact and sustainability

⚠️ Challenges & Risks +

  • Resource challenges impacting the full rollout of the Health and Wellbeing program.
  • Initial UK-centric approach to the Health and Wellbeing program.
  • Decreased employee survey participation rate (from 82% to 68.4%).
  • Increased Scope 3 emissions (purchased pharmaceuticals) by 31%.

📋 Report Information

Reporting Period: 2022
Frameworks: GRI